AstraZeneca axes another R&D track on durvalumab after once again falling behind rivals
It’s not easy being fourth.
The R&D team at AstraZeneca had thought that its single-arm study for its Phase II trial of the PD-L1 checkpoint durvalumab might have offered a shortcut to an approval for second-line head and neck cancer. But Merck easily beat them to the market with Keytruda for head and neck with a nod in August and now Bristol-Myers is breathing down its neck in the hope that they can catapult ahead — which would be welcome after the embarrassing lung cancer debacle.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.